Contract 75A50122C00061

Mapp Biopharmaceutical, Inc. · Department Of Health And Human Services · September 27, 2022

Cost Plus Fixed FeeFull & Open CompetitionNAICS 541714

Mapp Biopharmaceutical, Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 27, 2022 for $159.72 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in San Diego, CA. It was awarded under full and open competition. The contract has been modified 3 times since the base award It uses cost-plus contract pricing. The most recent modification was on March 12, 2026. If all options are exercised, the contract could reach $906.65 million.

Obligated to date
$159.72M
$159,719,724
Current value
$184.79M
Potential value
$906.65M
if all options exercised
Modifications
3
Latest March 12, 2026

Contract details

PIID
75A50122C00061
Award type
Definitive Contract
Pricing
Cost Plus Fixed Fee
Set-aside
No Set Aside Used.
Competition
Full And Open Competition
NAICS
541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
Product / service
Drugs And Biologicals
Place of performance
San Diego, CA
First action
September 27, 2022
Latest action
March 12, 2026

Description

PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP TO MAPP CONTACT 21C, EXTEND POP FOR CLIN 0001 & 0006

Modification timeline

  • March 12, 2026
    Mod P00018 · Supplemental Agreement For Work Within Scope
    $184.79M
  • July 11, 2025
    Mod P00017 · Supplemental Agreement For Work Within Scope
    PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP
    $184.79M
  • August 7, 2024
    Mod P00011 · Other Administrative Action
    PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE RATE LETTER MOD
    $134.84M
  • September 27, 2022
    Base award
    PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES
    $134.84M

Similar contracts

RecipientAgencyDateObligated
Vericel CorporationDepartment Of Health And Human ServicesApril 1, 2026$34.88M
Ceramedix Holding, LlcDepartment Of Health And Human ServicesMarch 31, 2026$4.22M
American College Of Medical Toxicology, Inc.Department Of Health And Human ServicesMarch 31, 2026$0
Glaxosmithkline, LlcDepartment Of Health And Human ServicesMarch 31, 2026$7.79M
Care Access Research LlcDepartment Of Health And Human ServicesMarch 31, 2026$2.55M
Pattern Bioscience, Inc.Department Of Health And Human ServicesMarch 31, 2026$22.50M

Top contractors in NAICS 541714

Lifetime obligated dollars across all federal contracts in this NAICS code.

#ContractorContractsObligated
1Amgen USA Inc1$59.99M
2Vericel Corporation1$34.88M
3Spectral Md, Inc.1$31.67M
4Ppd Development Lp6$31.12M
5L3 Technologies, Inc.1$22.00M
6Technical Resources International, Inc.6$21.80M
7Abbott Laboratories1$21.01M
8Paratek Pharmaceuticals, Inc1$17.47M
9Ossium Health, Inc.1$12.39M
10Rho Federal Systems Division Inc1$8.00M

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract 75A50122C00061?

Contract 75A50122C00061 is a federal contract awarded to Mapp Biopharmaceutical, Inc. by Department Of Health And Human Services on September 27, 2022 for $159.72 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 3 times since the base award.

Who won contract 75A50122C00061?

Mapp Biopharmaceutical, Inc. won contract 75A50122C00061 from Department Of Health And Human Services.

How much is contract 75A50122C00061 worth?

Contract 75A50122C00061 has obligated $159.72 million to date, with a total potential value of $906.65 million if all options are exercised.